Skip to main content
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. — Investor Relations & Filings

Ticker · AARD ISIN · US0029421007 US Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2025-01-23 Capital/Financing Update
Country US United States of America
Listing US AARD

About Aardvark Therapeutics, Inc.

https://aardvarktherapeutics.com/

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel, small-molecule therapeutics. The company focuses on activating innate homeostatic pathways to address metabolic diseases and conditions associated with hunger. Its lead product candidate, ARD-101, is an oral investigational drug designed for the treatment of hyperphagia, particularly in rare genetic diseases. ARD-101 functions primarily within the digestive tract by activating bitter taste receptors (TAS2Rs), which triggers the local release of satiety hormones. These hormones then send signals to the brain to suppress hunger. The company aims to become a leader in treating hunger, with potential applications for obesity and related conditions.

Recent filings

Filing Released Lang Actions
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) to register securities for sale to the public. It includes detailed information about the company, its business, management, financial condition, risk factors, and the offering itself. This is not an annual report, earnings release, or any other type of financial report but a registration statement for a capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed prospectus information typical of an S-1 filing. Hence, the classification is CAP with high confidence.
2025-01-23 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding comments on a Draft Registration Statement on Form S-1 for Aardvark Therapeutics, Inc. It discusses responses to SEC staff comments on the company's registration statement amendments. The document is not a financial report, earnings release, or management discussion but rather a regulatory correspondence related to the registration process for securities offering. It is a regulatory filing responding to SEC comments on a draft registration statement, which fits the category of Regulatory Filings (RNS). The document length is 3373 characters, which is relatively short and consistent with a comment response letter rather than a full report.
2024-12-20 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 100% confidence The document is a confidential draft of a Form S-1 Registration Statement submitted to the SEC by Aardvark Therapeutics, Inc. The Form S-1 is used for initial public offerings (IPOs) to register securities under the Securities Act of 1933. The text includes detailed information about the company, its business, management, risk factors, use of proceeds, and other disclosures typical of an IPO prospectus. It is not an annual report, earnings release, or any other type of financial report but a registration statement for capital raising and public listing. Therefore, the filing type corresponds to a Capital/Financing Update (CAP) as it relates to the company's initial public offering and registration of securities.
2024-12-20 English
Regulatory Filings 2024
Regulatory Filings
2024-12-10 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter from a law firm to the SEC Division of Corporation Finance regarding comments on a Draft Registration Statement on Form S-1 for Aardvark Therapeutics, Inc. It discusses responses to SEC comments on the company's S-1 filing, which is a registration statement for an initial public offering (IPO). The document is not the registration statement itself but a comment letter response. It contains no financial statements or detailed financial data but is a regulatory correspondence related to the registration process. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2024-11-27 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a confidential draft of a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a preliminary prospectus for an initial public offering (IPO) of common stock by Aardvark Therapeutics, Inc. The text includes detailed information about the company, its business, risk factors, management, and financial data, typical of an IPO registration statement. Form S-1 is specifically used for registration of securities for public offering under the Securities Act of 1933. This type of filing is related to capital raising and financing activities. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a brief summary, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the best classification is CAP with high confidence.
2024-11-27 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.